What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has made a revolutionary difference in the treatment of malignant tumors, and considerably extended patients’ overall survival (OS). In the world medical profession, however, there still reaches no clear consensus on the optimal dura...
Main Authors: | Jiaxin Yin, Yuxiao Song, Jiazhuo Tang, Bicheng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.983581/full |
Similar Items
-
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
by: Maxime Borgeaud, et al.
Published: (2023-02-01) -
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01) -
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
by: Matteo Perrino, et al.
Published: (2023-01-01) -
Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)
by: Society of Onco-Endocrinology of Chinese Anti-Cancer Association
Published: (2023-10-01) -
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
by: Kathryn DeCarli, et al.
Published: (2022-08-01)